The Biggest Challenge in Medicine with Neil deGrasse Tyson & Dr. Linda Malkas
StarTalk・2 minutes read
Cancer treatments and research, highlighted on Star Talk, emphasize the complexity of treating cancer due to its similarities to healthy cells. Linda Malus's innovative approach targeting a specific domain on the PCNA molecule led to the discovery of AOH 1996, a promising compound currently in a phase one clinical trial showing effectiveness in killing cancer cells while sparing normal ones.
Insights
- Cancer cells mimic healthy cells, making treatment challenging due to their resemblance and continuous evolution, requiring innovative approaches like targeting the unique protein PCNA for effective therapy.
- AOH 1996, a compound targeting the PCNA molecule, shows promise in selectively killing cancer cells while sparing normal ones, with a phase one clinical trial demonstrating efficacy, highlighting the potential of personalized, non-toxic, and combination therapies to combat resistance and advance cancer treatment.
Get key ideas from YouTube videos. It’s free
Recent questions
What is the focus of cancer research?
Innovative treatments targeting unique cancer characteristics.
How does the immune system interact with cancer cells?
Eliminates cancer cells naturally.
What is the significance of molecular signatures in cancer treatment?
Personalized treatment based on unique tumor features.
How does AOH 1996 differ from traditional cancer treatments?
Selectively kills cancer cells while sparing normal cells.
What is the role of combination therapies in cancer treatment?
Combating cancer resistance and reducing toxicity.
Related videos
TEDx Talks
A breakthrough in eradicating cancer | Eric Tran | TEDxPortland
SciShow
Everything We've Learned About Cancer | Compilation
Dr Chatterjee Clips
Food As Medicine: Use Food To Heal The Body & STARVE Cancer | Dr. William Li
TEDx Talks
What tumors eat -- and how to poison them | Dr. Christal Sohl | TEDxTulsaCC
TED-Ed
How to biohack your cells to fight cancer - Greg Foot
Summary
00:00
"Star Talk: Cancer Treatments Targeting PCNA"
- Cancer treatments are explored on Star Talk, aiming to eliminate the disease that mimics human cells.
- Neil deGrasse Tyson hosts with co-hosts Gary O'Reilly and Chuck Nice.
- A cancer researcher at City of Hope Cancer Research and Treatment Center pursues innovative treatments.
- The researcher emphasizes the challenge of treating cancer due to its resemblance to healthy cells.
- Cancer is likened to a predator constantly evolving and difficult to treat.
- The body naturally produces cancer cells daily, but the immune system eliminates them.
- DNA damage occurs daily, but repair systems maintain cellular health.
- Cancer cells continuously mutate to evade immune surveillance, akin to a survival mechanism.
- A unique protein, proliferating cell nuclear antigen (PCNA), is identified as a potential target for cancer treatment.
- The PCNA molecule in cancer cells differs from that in normal cells, offering a promising avenue for targeted therapy.
17:48
Innovative Cancer Treatment: AOH 1996 Success
- The movie about Linda Malus focuses on treating certain cancers, emphasizing the importance of a heart issue over spite as fuel for long-term success.
- Linda's unique approach involves targeting a specific domain on the PCNA molecule to combat cancer, leading to the discovery of a small domain crucial for distinguishing cancer from normal cells.
- Through extensive molecular biology work, Linda identified a pocket within the PCNA molecule, enabling the screening of 6.5 million molecules using AI technology to find compounds that selectively kill cancer cells.
- Out of the 53 compounds identified, five effectively killed cancer cells while sparing normal cells, with one unique compound progressing to become AOH 1996, currently in a phase one clinical trial with humans.
- The phase one trial aims to determine the maximum tolerated dose in humans, with promising results from animal testing showing no toxicity and inhibition of tumor growth.
- The FDA granted permission for the phase one trial after successful animal testing, with subsequent phases focusing on efficacy trials to assess the drug's impact on cancer patients.
- Cancer is now viewed as a molecular signature disease, with each tumor having unique features that require personalized treatment based on the individual's molecular signature.
- Metastasis and molecular signatures play distinct roles in cancer progression, with metastasis involving the spread of cancer cells to other organs and molecular signatures influencing gene regulation for potential therapy development.
- Harnessing the immune system through immunotherapy is a key area of research, aiming to exploit the body's natural defenses against cancer cells, although cancer's adaptability remains a challenge.
- AOH 1996 is administered as a pill twice a day to maintain a consistent presence in the body, with a five-hour half-life ensuring continuous drug efficacy and patient convenience.
36:00
Optimizing Cancer Treatment with AOH 1996
- Antibiotics are crucial, and it's vital to take them as prescribed to avoid issues like not finishing the course.
- The frequency of medication intake, like every eight hours, is related to the drug's half-life.
- Cancer treatment often involves platinum compounds that target DNA but can harm healthy cells due to their inability to differentiate.
- Combination therapies, like AOH 1996, are being explored to combat cancer resistance, moving away from monotherapy.
- AOH 1996 shows promise in being non-toxic and effective, complementing existing drugs and potentially reducing their toxicity.
- Resistance to cancer treatments is a significant challenge, but AOH 1996 has shown resistance prevention in studies.
- Targeting hubs like PCNA in cancer cells could be a more effective strategy than focusing on single enzymes, leading to more precise treatments based on molecular signatures.
